Harnessing programmed death-ligand 1 as a prognostic marker in OSCC: Challenges and opportunities in the era of immunotherapy
• Evaluating the role of PD-L1 as a prognostic marker in oral squamous cell carcinoma (OSCC). • Analyzing the challenges associated with PD-L1 assessment in the context of immunotherapy. • Exploring opportunities for leveraging PD-L1 to improve treatment outcomes in OSCC. • Discussing the evolving landscape of immunotherapy and its impact on PD-L1 as a biomarker in OSCC.
Authors
- Madhan Krishnan (ORCID: https://orcid.org/0000-0003-3464-9329)
- Shyamaladevi Babu (ORCID: https://orcid.org/0000-0001-7407-5273)
Institutions
- Chettinad Academy of Research and Education (IN)
Publication Details
- Journal
- Oral Oncology Reports
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.oor.2024.100641
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00